Business
Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients
Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc.
About this update from Biodesix, Inc.
[{"type":"text","content":"\nDiagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodesix’s ability to offer rapid, accurate assessment of patients, which guide physician treatment strategies for their cancer patients.\n\nU.S. Patent 10,950,348, titled, “Predictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death 1 (PD-1) Checkpoint Protein and Classifier Development Methods,” covers a test that classifies patients based on their responses, or failures to respond, to immunotherapies. This diagnostic methodology is designed to stratify patients with lung cancer based on their likelihood to respond to immunotherapies.\n\n“Immunotherapy drugs have made tremendous headway in the treatment of many types of cancers, including lung cancer and melanoma,” said Robert Georgantas, III, Ph.D., Senior Vice President of Research and Translational Science at Biodesix. “However, only a subset of patients benefits from these treatments. Predicting who will or will not respond to immunotherapy is imperative for better stratification of patients by immune response to foster treatment personalization and optimal outcome. Additionally, response prediction can help our biopharma research partners develop drug regimens to improve patient survival with these types of drugs.”\n\nU.S. Patent 10,870,891, “Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood,” covers a novel method for detecting fragmented ribonucleic acid (RNA) in whole blood samples. The method uniquely purifies and amplifies RNA once it is isolated and can ultimately be used in tests that identify or quantify tumor genes and mutations in a host of downstream applications.\n\n“This method is especially valuable because it further improves the performance of our blood-based technologies,” Gary Pestano, Ph.D., Chief Development Officer at Biodesix, said of the novel dia...